Despite the availability of a safe and efficacious vaccine, new cases of in
fection by hepatitis B virus (HBV) still occur at a substantial rate. This
increases the current prevalence of chronic HBV carriers (10% of newly infe
cted subjects) and in the long run, will raise the incidence of chronic liv
er disease. The surveillance of viral hepatitis commenced in December 1990
by the French sentinel network for electronic surveillance of communicable
diseases. Between 1991 and 1996, a decrease in the annual incidence was obs
erved although it was not significant (p = 0.06). The mean number of cases
for this period was 12 per 100,000 inhabitants. The sex ratio (M/F) was 1.6
(p < 0.01) and the median age, 32 years. Heterosexual transmission was sus
pected in 25% of cases, home-bisexual transmission in 10%, use of injected
drugs in 19%, percutaneous exposure in 9%, and blood transfusion or hemodia
lysis in 6%. Although the incidence of HBV infection is decreasing, the pre
valence of chronic infection will continue to rise. However, the universal
hepatitis B immunisation strategy proposed by WHO will dramatically limit t
he expansion of the population of chronically infected subjects if high cov
erage is achieved rapidly.